Daclatasvir-d6

Daclatasvir-d6 is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively[1][2][3].

Product Specifications

CAS Number

[1801709-41-0]

Product Name Alternative

BMS-790052-d6; EBP 883-d6

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

HCV; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Others

Applications

COVID-19-anti-virus

Field of Research

Infection

Purity

99.64

Solubility

10 mM in DMSO

Smiles

[2H]C([2H])([2H])OC(N[C@@H](C(C)C)C(N1[C@H](C2=NC=C(C3=CC=C(C4=CC=C(C5=CN=C([C@H]6N(CCC6)C([C@H](C(C)C)NC(OC([2H])([2H])[2H])=O)=O)N5)C=C4)C=C3)N2)CCC1)=O)=O

Molecular Formula

C40H44D6N8O6

Molecular Weight

744.91

Precautions

H315, H319, H335

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]David B Ascher, et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014 Apr 23;4:4765.|[3]Min Gao, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010 May 6;465 (7294) :96-100.|[4]Seung-Hoon Lee, et al. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep. 2018 Aug 20;8 (1) :12469.|[5]Tomomi Furihata, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014 Aug;58 (8) :4555-64.